Table 2.

Multivariate analysis in 83 lung transplant recipients.

	Coefficient	95% CI	p value
CD4 T-cell counta
Viral infections in blood (yes vs. no)b	−11.1	−50.0 to 27.9	0.578
Gender (males vs. females)	45.7	−60.5 to 151.9	0.399
Age (per year)	1.3	−2.3 to 4.9	0.494
Nadir CD4 T-cell (< 200 vs. > 200 cells/μl)	−423.4	−516.8 to −329.9	<0.001
Induction therapy (ATG vs. no)	−95.9	−203.1 to 11.1	0.079
Immunosuppressive therapyc	−45.1	−138.7 to 48.6	0.345
Rejection episodes (yes vs. no)	−20.2	−65.3 to 24.9	0.380
Viral infections in BAL (yes vs. no)b	−28.4	−-54.8 to −1.9	0.036
Gender (males vs. females)	45.1	−61.9 to 152.1	0.409
Age (per year)	1.3	−2.3 to 4.9	0.473
Nadir CD4 T-cell (< 200 vs. > 200 cells/μl)	−421.7	−515.9 to −327.5	<0.001
Induction therapy (ATG vs. no)	−93.9	−201.7 to 13.8	0.088
Immunosuppressive therapyc	−43.1	−137.3 to 51.1	0.370
Rejection episodes (yes vs. no)	−10.6	−56.3 to 35.1	0.649
CD8 T-cell counta
Viral infections in blood (yes vs. no)b	−36.2	−101.8 to 29.4	0.279
Gender (males vs. females)	206.8	44.1 to 369.6	0.013
Age (per year)	−4.7	−10.2 to 0.8	0.096
Nadir CD4 T-cell (< 200 vs. > 200 cells/μl)	−300.6	−443.1 to −158.1	<0.001
Induction therapy (ATG vs. no)	−58.9	−223.3 to 105.3	0.482
Immunosuppressive therapyc	44.7	−98.9 to 188.4	0.542
Rejection episodes (yes vs. no)	64.6	−11.2 to 140.4	0.095
Viral infections in BAL (yes vs. no)b	−12.1	−56.9 to 32.7	0.596
Gender (males vs. females)	208.6	45.1 to 372.0	0.012
Age (per year)	−4.7	−10.2 to 0.9	0.098
Nadir CD4 T-cell (< 200 vs. > 200 cells/μl)	−303.2	−446.2 to −160.1	<0.001
Induction therapy (ATG vs. no)	−53.9	−218.6 to 110.9	0.522
Immunosuppressive therapyc	39.9	−103.9 to 183.8	0.587
Rejection episodes (yes vs. no)	69.9	−7.2 to 147.2	0.076

CI, confidence interval; ATG, antithymocyte globulin; BAL, bronchoalveolar lavage.

^aDependent variable.

^bBoth opportunistic and community-acquired viral infections.

^cCyclosporine A or tacrolimus/azathioprine/steroids vs. Cyclosporine A or tacrolimus/mycophenolate mofetil/steroids.